Breast cancer survival and hormone replacement therapy - A cohort analysis

DiSaia, PJ Brewster, WR Ziogas, A Anton-Culver, H

Pj. Disaia et al., Breast cancer survival and hormone replacement therapy - A cohort analysis, AM J CL ONC, 23(6), 2000, pp. 541-545

25

INGLESE

Article

Oncology

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

0277-3732 → ACNP

23

6

2000

541 - 545

ISI

0277-3732(200012)23:6<541:BCSAHR>2.0.ZU;2-I

Controversy exists regarding the safety of hormone replacement therapy (HRT ) after a diagnosis of breast cancer. The objective of this study is to per form a matched cohort analysis to evaluate the impact of HRT on mortality i n breast cancer survivors. Patients with breast cancer who received HRT aft er diagnosis of breast cancer were identified. Control subjects were identi fied from the regional cancer registry. Matching criteria included age at d iagnosis, stage of breast cancer, and year of diagnosis. Controls were sele cted only if they were alive at the time of initiation of HRT of the matche d case. Only subjects not included in a previously reported matched analysi s were selected. One hundred twenty-five cases were matched with 362 contro ls. Ninety-eight percent (123/125) of the cases received systemic estrogen; 90/125 (72%) also received a progestational agent. The median interval bet ween diagnosis of breast cancer and initiation of HRT was 46 months (range 0-401 months). The median duration of HRT was 22 months (range 1-357 months ). The risk of death was lower among the HRT survivors; odds ratio 0.28 (95 % confidence interval 0.11-0.71). This analysis does not suggest that HRT a fter the treatment of breast cancer is associated with an adverse outcome.